Nicholas J W Rattray1, Georgia Charkoftaki1, Zahra Rattray2, James E Hansen2,3, Vasilis Vasiliou1, Caroline H Johnson1. 1. Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, USA, 06520. 2. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Yale University, CT, USA 06520. 3. Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA 06520.
Abstract
PURPOSE OF REVIEW: In this review we discuss how environmental exposures predominate the etiology of colorectal cancer (CRC). With CRC being a personalized disease influenced by genes and environment, our goal was to explore the role metabolomics can play in identifying exposures, assessing the interplay between co-exposures, and the development of personalized therapeutic interventions. RECENT FINDINGS: Approximately 10 % of CRC cases can be explained by germ-line mutations, whereas the prevailing majority are caused by an initiating exposure event occurring decades prior to diagnosis. Recent research has shown that dietary metabolites are linked to a procarcinogenic or protective environment in the colon which is modulated by the microbiome. In addition, excessive alcohol has been shown to increase the risk of CRC and is dependent on diet (folate), the response of microbiome, and genetic polymorphisms within the folate and alcohol metabolic pathways. Metabolomics can not only be used to identify this modulation of host metabolism, which could affect the progression of the tumors but also response to targeted therapeutics. SUMMARY: This review highlights the current understanding of the multifaceted etiology and mechanisms of CRC development but also highlights where the field of metabolomics can contribute to a greater understanding of environmental exposure in CRC.
PURPOSE OF REVIEW: In this review we discuss how environmental exposures predominate the etiology of colorectal cancer (CRC). With CRC being a personalized disease influenced by genes and environment, our goal was to explore the role metabolomics can play in identifying exposures, assessing the interplay between co-exposures, and the development of personalized therapeutic interventions. RECENT FINDINGS: Approximately 10 % of CRC cases can be explained by germ-line mutations, whereas the prevailing majority are caused by an initiating exposure event occurring decades prior to diagnosis. Recent research has shown that dietary metabolites are linked to a procarcinogenic or protective environment in the colon which is modulated by the microbiome. In addition, excessive alcohol has been shown to increase the risk of CRC and is dependent on diet (folate), the response of microbiome, and genetic polymorphisms within the folate and alcohol metabolic pathways. Metabolomics can not only be used to identify this modulation of host metabolism, which could affect the progression of the tumors but also response to targeted therapeutics. SUMMARY: This review highlights the current understanding of the multifaceted etiology and mechanisms of CRC development but also highlights where the field of metabolomics can contribute to a greater understanding of environmental exposure in CRC.
Authors: Manuela G Neuman; Samuel W French; Samir Zakhari; Stephen Malnick; Helmut K Seitz; Lawrence B Cohen; Mikko Salaspuro; Andreea Voinea-Griffin; Andrei Barasch; Irina A Kirpich; Paul G Thomes; Laura W Schrum; Terrence M Donohue; Kusum K Kharbanda; Marcus Cruz; Mihai Opris Journal: Exp Mol Pathol Date: 2017-01-07 Impact factor: 3.362
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: Y Ji; S Hebbring; H Zhu; G D Jenkins; J Biernacka; K Snyder; M Drews; O Fiehn; Z Zeng; D Schaid; D A Mrazek; R Kaddurah-Daouk; R M Weinshilboum Journal: Clin Pharmacol Ther Date: 2010-11-24 Impact factor: 6.875
Authors: Ryan Abo; Scott Hebbring; Yuan Ji; Hongjie Zhu; Zhao-Bang Zeng; Anthony Batzler; Gregory D Jenkins; Joanna Biernacka; Karen Snyder; Maureen Drews; Oliver Fiehn; Brooke Fridley; Daniel Schaid; Naoyuki Kamatani; Yusuke Nakamura; Michiaki Kubo; Taisei Mushiroda; Rima Kaddurah-Daouk; David A Mrazek; Richard M Weinshilboum Journal: Pharmacogenet Genomics Date: 2012-04 Impact factor: 2.089
Authors: Sophie Leclercq; Sébastien Matamoros; Patrice D Cani; Audrey M Neyrinck; François Jamar; Peter Stärkel; Karen Windey; Valentina Tremaroli; Fredrik Bäckhed; Kristin Verbeke; Philippe de Timary; Nathalie M Delzenne Journal: Proc Natl Acad Sci U S A Date: 2014-10-06 Impact factor: 11.205
Authors: Stephen J D O'Keefe; Jia V Li; Leo Lahti; Junhai Ou; Franck Carbonero; Khaled Mohammed; Joram M Posma; James Kinross; Elaine Wahl; Elizabeth Ruder; Kishore Vipperla; Vasudevan Naidoo; Lungile Mtshali; Sebastian Tims; Philippe G B Puylaert; James DeLany; Alyssa Krasinskas; Ann C Benefiel; Hatem O Kaseb; Keith Newton; Jeremy K Nicholson; Willem M de Vos; H Rex Gaskins; Erwin G Zoetendal Journal: Nat Commun Date: 2015-04-28 Impact factor: 14.919
Authors: Chelsea L Gibson; Simona G Codreanu; Alexandra C Schrimpe-Rutledge; Cassandra L Retzlaff; Jane Wright; Doug P Mortlock; Stacy D Sherrod; John A McLean; Randy D Blakely Journal: Mol Omics Date: 2018-06-12
Authors: Yuping Cai; Nicholas J W Rattray; Qian Zhang; Varvara Mironova; Alvaro Santos-Neto; Engjel Muca; Ana K Rosen Vollmar; Kuo-Shun Hsu; Zahra Rattray; Justin R Cross; Yawei Zhang; Philip B Paty; Sajid A Khan; Caroline H Johnson Journal: Metabolites Date: 2020-06-19
Authors: Jingwei Cai; Robert G Nichols; Imhoi Koo; Zachary A Kalikow; Limin Zhang; Yuan Tian; Jingtao Zhang; Philip B Smith; Andrew D Patterson Journal: mSystems Date: 2018-11-06 Impact factor: 6.496
Authors: Nicholas J W Rattray; Nicole C Deziel; Joshua D Wallach; Sajid A Khan; Vasilis Vasiliou; John P A Ioannidis; Caroline H Johnson Journal: Hum Genomics Date: 2018-01-26 Impact factor: 4.639